Phase I/II trial of outpatient PEG-INTRON® with interleukin-2 (IL-2) in advanced renal cell carcinoma (RCC), a cytokine working group study

被引：0
|
作者：
Mehrabi, J
Atkins, M
Sosman, J
Logan, T
Margolin, K
Dutcher, J
Urba, W
Lau-Schwabe, A
Clark, J
机构：
[1] Loyola Univ, Maywood, IL 60153 USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] Vanderbilt Univ, Nashville, TN USA
[4] Indiana Univ, Indianapolis, IN 46204 USA
[5] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[6] Our Lady Mercy Med Ctr, Bronx, NY USA
[7] Providence Portland Med Ctr, Portland, OR USA
来源：
JOURNAL OF IMMUNOTHERAPY | 2004年 / 27卷 / 06期
关键词：
D O I：
10.1097/00002371-200411000-00068
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S18 / S18
页数：1
相关论文
共 50 条
  • [1] Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: A cytokine working group study
    Clark, Joseph I.
    Mehrabi, Jessica
    Sosman, Jeffrey A.
    Logan, Theodore F.
    Margolin, Kim A.
    Dutcher, Janice P.
    Urba, Walter J.
    Ernstoff, Marc S.
    McDermott, David F.
    Lau, Ann M.
    Atkins, Michael B.
    JOURNAL OF IMMUNOTHERAPY, 2007, 30 (08) : 839 - 846
  • [2] Phase I/II trial of a novel regimen of GM-CSF, IL-2 and pegylated interferon-alpha2b (PEG-Intron) for stage IV melanoma and renal cell carcinoma (RCC).
    Odaimi, M
    El-Jassous, I
    Richa, E
    Forte, F
    Terjanian, T
    Vesoniaraki, M
    Lowry, J
    Murukutla, S
    Dhar, M
    Burton, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 728S - 728S
  • [3] Phase Ib/II trial of interleukin-2 (IL-2) and nivolumab in metastatic clear cell renal cell cancer (RCC)
    Yentz, S.
    Alva, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Combined levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma - A phase II study
    Creagan, ET
    Hestorrf, RD
    Suman, VJ
    Mailliard, JA
    Nair, S
    Krook, JE
    Kugler, JW
    Marschke, RF
    Michalak, JC
    Tschetter, LK
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (02): : 139 - 141
  • [5] A phase I trial of Interleukin-2 (IL-2) and Pembrolizumab (Pembro) Combination Therapy for patients with advanced renal cell carcinoma
    Tykodi, Scott
    Whitney, Johanna
    Dakhil, Sumia
    Bergren, Eleanor
    Vivian Nguyen
    Kiriluk, Samantha
    Bhatia, Shailender
    Thompson, John
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [6] A PHASE-I-II TRIAL OF OUTPATIENT HIGH-DOSE INTERLEUKIN-2 (IL-2)
    RICHARDS, JM
    RAMMING, K
    BARKER, E
    VOGELZANG, NJ
    CLINICAL RESEARCH, 1987, 35 (06): : A864 - A864
  • [7] Phase I trial of subcutaneous (SC), outpatient interleukin-2 (IL-2) for patients with advanced mycosis fungoides (MF).
    Gold, PJ
    Thompson, JA
    Lindgren, C
    Kern, D
    Fefer, A
    BLOOD, 1996, 88 (10) : 3493 - 3493
  • [8] Interleukin-2 (IL-2) chrono-infusion (CHI) in metastatic renal cell carcinoma (mRCC): A phase I/II study.
    Lo Re, Giovanni
    Santeufemia, Davide Adriano
    Lenardon, Oliviero
    Talamini, Renato
    Del Conte, Alessandro
    Marus, Wally
    Nicolosi, Gianluigi
    Mancinelli, Paolo
    Tumolo, Salvatore
    Garbeglio, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [9] A phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab in patients with metastatic renal cell carcinoma (mRCC)
    Garcia, J. A.
    Rini, B. I.
    Mekhail, T.
    Triozzi, P.
    Elson, P.
    Nemec, C.
    Bukowski, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma: A Cytokine Working Group (CWG) Study
    Dandamudi, Uday B.
    Ghebremichael, Musie
    Sosman, Jeffrey A.
    Clark, Joseph I.
    McDermott, David F.
    Atkins, Michael B.
    Dutcher, Janice P.
    Urba, Walter J.
    Regan, Meredith M.
    Puzanov, Igor
    Crocenzi, Todd S.
    Curti, Brendan D.
    Vaishampayan, Ulka N.
    Crosby, Nancy A.
    Margolin, Kim A.
    Ernstoff, Marc S.
    JOURNAL OF IMMUNOTHERAPY, 2013, 36 (09) : 490 - 495
12345